Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals IN (IN.TO)

Inmed Pharmaceuticals IN (IN.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Inmed Pharmaceuticals IN 815 West Hastings Street Suite 310 Vancouver BC V6C 1B4 CAN

https://www.inmedpharma.com P: 604-669-7207 F: 778-945-6800

Description:

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

Key Statistics

Overview:

Market Capitalization, $K 33,732
Shares Outstanding, K 8,051
Annual Sales, $ 4,136 K
Annual Net Income, $ -7,948 K
Last Quarter Sales, $ 1,240 K
Last Quarter Net Income, $ -1,478 K
60-Month Beta 2.08
% of Institutional Shareholders 0.45%

Growth:

1-Year Return -47.10%
3-Year Return -87.30%
5-Year Return 58.71%

Per-Share Information:

Latest Earnings Date 05/13/21
Earnings Per Share ttm -1.33
Dividend Payout Ratio 0.00%
Most Recent Split 1-33 on 07/03/20

IN.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -46.86%
Return-on-Assets % -39.48%
Profit Margin % -192.18%
Debt/Equity 0.00
Price/Sales N/A
Price/Book 3.62
Book Value/Share 1.16
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar